**18. Aortic aneurysm and cholesterol**

Aneurysm is defined as enlarging the diameter of artery, local or diffuse, by 50% or more relative to normal. According to localization, it is divided into thoracic and abdominal. Aortic aneurysms are 80% in abdominal location [32]. It is a chronic disease associated with inflammation of the aortic wall. It is suggested that the vessel is formed as a result of elasticity and power loss of the aortic wall after occlusion of vasa vasorum.

In the population with abdominal aortic aneurysm, association with other atherosclerotic cardiovascular diseases was frequently observed. The presence of abdominal aortic aneurysm was frequently associated with other atherosclerotic cardiovascular diseases. Smoking, age, and male sex increases the risk of aortic aneurysm. While intimal atheroma and thrombosis process are present in both diseases, elastin fragmentation and adventitial chronic inflammation are limited to aortic aneurysms [33, 34].

[5] Wiviott SD et al. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID study). The American

Role of Cholesterol as a Risk Factor in Cardiovascular Diseases

http://dx.doi.org/10.5772/intechopen.76357

105

[6] Nicholls SJ et al. Impact of statins on progression of atherosclerosis: Rationale and design of SATURN (Study of coronary atheroma by in travascular ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion. 2011;

[7] West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study

[8] Downs JR et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;

[9] Sever PS et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac outcomes trial—Lipid lowering arm (ASCOT-LLA): A

[10] Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre

[11] Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised place-

[12] Ridker PM et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;**98**(9):839-844

[13] Schwartz GG et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA.

[14] Nicholls SJ et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal. 2015;**170**(6):1061-1069 [15] Norata GD et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arteriosclerosis, Thrombosis, and

[16] Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: A modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends

[17] Aim-High Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular

multicentre randomised controlled trial. The Lancet. 2003;**361**(9364):1149-1158

randomised placebo-controlled trial. The Lancet. 2004;**364**(9435):685-696

Journal of Cardiology. 2009;**104**(1):29-35

(WOSCOPS). Circulation. 1998;**97**(15):1440-1445

bocontrolled trial. The Lancet. 2002;**360**(9326):7-22

**27**(6):1119-1129

**279**(20):1615-1622

2001;**285**(13):1711-1718

Vascular Biology. 2008;**28**(5):925-931

in Cardiovascular Medicine. 2010;**20**(2):35-40

In the tromsø study, there was a relation between the intima media thickness and the incidence of coronary artery disease and abdominal aortic aneurysm, but no correlation with aortic diameter [35]. The relationship between lipid level and aortic aneurysm has not been clearly elucidated [36]. The data for the studies are based on the similarity of risk factors for atherosclerosis and aortic aneurysm risk factors.
